All Oncology News

Thomas E. Stinchcombe, MD, discussea existing and emerging first-line regimens coming through the pipeline for the treatment of patients with non–small cell lung cancer.

Laura M. Freedman, MD, discusses the impact of the updated NCCN guidelines on clinical applications of radiation therapy in patients with breast cancer.

Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic CRPC.

Ruta D. Rao, MD, elaborates on the findings of the ABCSG-16, SOFT, and TEXT clinical trials and how they have shaped adjuvant treatment for ER-positive breast cancer.

The FDA has announced plans to ease the development of genetic and genomic-based tests and introduced guidelines designed to accelerate the submission process for investigational cancer drugs and biological products.

The ongoing phase IIIb PRONOUNCE trial is seeking to determine if the gonadotropin-releasing hormone receptor antagonist degarelix (Firmagon) is more likely to reduce cardiovascular events in patients with advanced prostate cancer and CVD versus the GnRH agonist receptor leuprolide.

There are multiple therapeutic options in development for the treatment of patients with HER2-positive breast cancer, further adding to the regimens available, explains Frances Valdes-Albini, MD.

Investigators found that autologous stem-cell transplantation improved overall survival and reduced treatment-related mortality in patients with immunoglobulin light chain amyloidosis.

Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.

R. Kate Kelley, MD, discusses the incidence of and risk factors for HCC, and emphasizes the sequence of clinical trials that characterized the field in 2017.

Benny Weksler, MD, FACS, discusses the use of surgery in a biomarker-driven and drug-dependent era and highlights other cases in which surgery can benefit patients with NSCLC.

Adjuvant axitinib did not extend disease-free survival versus placebo for patients at high risk of recurrent renal cell carcinoma after nephrectomy, according to findings from the phase III ATLAS trial.

Data from the phase III POUT clinical trial demonstrated that adjuvant platinum-based chemotherapy improves disease-free survival and metastasis-free survival in patients with upper tract urothelial carcinoma.

Katherine Van Loon, MD, MPH, discusses the emerging use of neoadjuvant therapy and nonoperative approaches for patients with locally advanced rectal cancer.

Ari VanderWalde, MD, explains his trepidation with combinations of chemotherapy and immunotherapy in NSCLC.

The incidence of neuroendocrine tumors has increased 5-fold over the past 30 years, making it the second most prevalent diagnosis in gastrointestinal (GI) malignancies.

Margaret A. Tempero, MD, discusseds frontline treatment options in pancreatic cancer and emphasized the use and difficulties of conventional and incoming therapies across disease states.

Hyung L. Kim, MD, discusses perioperative systemic therapy for patients with kidney cancer.

Amit Gupta, MD, discusses the superiority of robotic cystectomy compared with open cystectomies and its relevance in the current treatment landscape of bladder cancer.

Single-agent treatment with the PD-1 inhibitor pembrolizumab improved overall survival versus chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer and a PD-L1 expression level ≥1%.

Mark D. Pegram, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer.

The FDA has granted a priority review to a new drug application for duvelisib for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.

Lori Ann Leslie, MD, provides expert insight on the latest developments in the field of follicular lymphoma.

Crizotinib induced a nearly 72% overall response rate and a median progression-free survival of almost 16 months in a single-arm phase II trial of 127 patients with ROS1-positive advanced non–small cell lung cancer (NSCLC).

The FDA has approved rucaparib for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Heather Han, MD, discusses emerging approaches for combating endocrine resistance in patients with ER-positive breast cancer.

The combination of the PD-1 inhibitor pembrolizumab and the IDO1 inhibitor epacadostat failed to improve progression-free survival versus single-agent pembrolizumab in patients with unresectable or metastatic melanoma, according to findings from the phase III ECHO-301/KEYNOTE-252 trial.

Ramamoorthy Nagasubramanian, MD, discusses the results of the phase I/II study of larotrectinib in pediatric patients.

The combination of nivolumab and ipilimumab induced an intracranial response of 46% in melanoma patients with asymptomatic, untreated brain metastases.

Michael Birrer, MD, PhD, discusses the effect that PARP inhibitors have had on the treatment of ovarian cancer, and the potential for combinations with these agents.